Financial Performance - Pharmaron reported a revenue increase of 25% year-over-year, reaching approximately RMB 2.5 billion in the latest quarter[18]. - The company's operating revenue for 2024 reached ¥12,275,774,875.03, representing a 6.39% increase compared to ¥11,537,996,314.78 in 2023[23]. - Net profit attributable to shareholders for 2024 was ¥1,793,350,814.50, marking a 12.01% increase from ¥1,601,096,033.08 in 2023[23]. - The company reported a basic earnings per share of ¥1.0133 for 2024, up 12.18% from ¥0.9033 in 2023[23]. - The company achieved operating revenue of 1,227,577.49 million yuan, a year-on-year increase of 6.39%[42]. - The company reported a decline in cash flow from operating activities, totaling 257,665.64 million yuan, down 6.42% year-on-year[42]. - The company reported a net cash flow from operating activities of ¥2,576,656,397.08 in 2024, down 6.42% from ¥2,753,538,934.89 in 2023[23]. - The company reported a significant increase in revenue, achieving a total of $1.5 billion, representing a 20% year-over-year growth[176]. Research and Development - Pharmaron's R&D investment increased by 30% to RMB 500 million, focusing on new drug development and innovative technologies[18]. - The company has expanded its capabilities in antibody-drug conjugates (ADC) and antisense oligonucleotides (ASO) as part of its research and development strategy[15]. - The company is actively exploring the application of artificial intelligence and machine learning in process chemistry R&D and quality management to enhance CDMO service efficiency[53]. - The company is committed to enhancing its ESG initiatives, focusing on sustainable practices in its operations[18]. - The company is focused on enhancing its research and development capabilities to better meet customer needs[115]. - The company is committed to improving high-quality, diverse biomedical databases and constructing reliable AI models, ensuring the sustainability of AI-enabled drug development[134]. Market Expansion and Strategy - Pharmaron is actively pursuing market expansion in Europe and North America, aiming to increase its global footprint[18]. - The company is continuously exploring market expansion opportunities and potential mergers and acquisitions to enhance its competitive position[15]. - The company plans to strengthen its leadership in small molecule R&D services while expanding into new drug modalities such as ADCs and peptides, with a focus on building an end-to-end service platform[121]. - The company aims to enhance collaboration across its multi-therapy platform, focusing on seamless integration in drug development stages and improving service quality through interdisciplinary cooperation[125]. - The company plans to expand its market presence in Southeast Asia, targeting a 20% market share by 2025[175]. Corporate Governance and Compliance - The company emphasizes the importance of accurate financial reporting, with all board members present for the approval of the annual report[3]. - The company has established a governance structure that complies with relevant laws and regulations, ensuring transparency in information disclosure[147]. - The company received an "A" rating in the information disclosure assessment from the Shenzhen Stock Exchange, reflecting its commitment to high-quality and transparent reporting[142]. - The company has established a comprehensive risk management framework to address various financial risks[1]. - The company is committed to maintaining a high standard of compliance with international regulations and quality standards to ensure the integrity of its services[126]. Employee Development and Corporate Culture - The company emphasizes a strong commitment to employee development and customer satisfaction, integrating personal career growth into the overall corporate strategy[73]. - The company has established a comprehensive talent management system to attract and retain skilled professionals, crucial for sustaining its competitive edge[128]. - The company has implemented a comprehensive compensation policy to attract and retain talent, including competitive salaries, bonuses, and various benefits[198]. - Training programs are tailored for different management levels, focusing on leadership development and performance improvement[199][200]. - The company emphasizes mental health and well-being through various employee support programs[198]. Financial Strategy and Investments - The company plans to distribute a cash dividend of 2 RMB per 10 shares, totaling approximately 356.11 million RMB for the 2023 fiscal year[144]. - The company will repurchase 9,608,288 A shares for a total amount of approximately 200.09 million RMB in 2024[145]. - The company has not utilized any raised funds during the reporting period[112]. - The company is considering strategic acquisitions to bolster its market position, with a budget of $100 million allocated for potential deals[176]. - The company is implementing hedging strategies to manage foreign exchange risks effectively[131]. Environmental and Social Responsibility - The company is actively responding to the national "dual carbon" strategy, focusing on reducing its environmental impact and promoting green transformation within its operations[142]. - The company reduced greenhouse gas emissions by 21% in 2024 compared to 2023, achieving its annual carbon reduction target[47]. - The company is committed to enhancing its ESG initiatives, focusing on sustainable practices in its operations[18]. Risk Management - The company has established a comprehensive risk management framework to address various financial risks[1]. - The company is actively monitoring international policy changes and trade dynamics to mitigate risks associated with geopolitical uncertainties[130]. - The company acknowledges potential risks in the drug development service market due to fluctuations in investment and budget changes from multinational pharmaceutical companies[127]. - The company faces risks related to intellectual property protection and is enhancing its confidentiality measures to safeguard client information[129].

Financial Performance - The company reported a net profit of 1.793 billion yuan for 2024, representing a year-on-year increase of 11.99% compared to 1.601 billion yuan in 2023 [1] - Revenue for 2024 reached 12.276 billion yuan, up 6.4% from 11.538 billion yuan in 2023 [1] - Basic earnings per share increased to 1.0133 yuan, a rise of 12.18% from 0.9033 yuan in the previous year [1] - The return on equity (ROE) slightly decreased to 13.70% from 13.91% in 2023 [1] Shareholder Structure - The top ten unrestricted shareholders collectively hold 99.14136 million shares, accounting for 57.62% of the circulating shares, with a decrease of 2.17455 million shares compared to the previous period [2] - HKSCC NOMINEES LIMITED remains the largest shareholder with 30.15020 million shares, representing 17.52% of the total share capital [3] - Shenzhen Xinchongkang Investment Partnership holds 26.08280 million shares, making up 15.16% of the total [3] Dividend Distribution - The company announced a dividend distribution of 0.2 yuan per share (including tax) [4]

康龙化成（北京）新药技术股份有限公司 募集资金专项存储及使用管理制度 中国 北京 2025 年 3 月 康龙化成（北京）新药技术股份有限公司 募集资金专项存储及使用管理制度 第一章 总则 第一条 为规范康龙化成（北京）新药技术股份有限公司（"公司"）募集资 金管理，提高募集资金使用效率，切实保护投资者利益，依照《中华人民共和国 公司法》《中华人民共和国证券法》等法律、法规、规范性文件及《康龙化成（北 京）新药技术股份有限公司公司章程》（"《公司章程》"）的有关规定，结合公司 实际情况，制定本制度。 第二条 本制度所称募集资金是指公司通过发行股票及其衍生品种，向投资 者募集并用于特定用途的资金，但不包括公司实施股权激励计划募集的资金。境 外上市外资股募集资金的使用管理按照香港证券及期货事务监察委员会、香港联 合交易所有限公司的相关规定执行。 第三条 公司董事会应当对募集资金投资项目的可行性进行充分论证，确信 投资项目具有较好的市场前景和盈利能力，有效防范投资风险，提高募集资金使 用效益。 第四条 公司应当建立并完善募集资金存储、使用、变更、监督和责任追究 的制度，明确募集资金使用的分级审批权限、决策程序、风险控 ...

康龙化成（北京）新药技术股份有限公司 独立非执行董事工作制度 中国 北京 2025 年 3 月 康龙化成（北京）新药技术股份有限公司 独立非执行董事工作制度 第一章 总 则 第一条 为完善康龙化成（北京）新药技术股份有限公司("公司")治理结 构，规范公司运作，更好的维护公司整体利益，保障全体股东特别是中小股东的 合法权益不受损害，根据《中华人民共和国公司法》（"《公司法》"）、中国证券监 督管理委员会（"中国证监会"）、公司股票上市地证券交易所的上市规则(包括但 不限于《香港联合交易所有限公司证券上市规则》（"《上市规则》"）)、和 《康龙化成（北京）新药技术股份有限公司章程》（"《公司章程》"）的规定，制 定《康龙化成（北京）新药技术股份有限公司独立非执行董事工作制度》（"本制 度"）。 第二条 独立非执行董事系指不在公司担任除独立非执行董事外的任何其他 职务，并与公司及其主要股东、实际控制人不存在直接或者间接利害关系，或者 其他可能影响其进行独立客观判断的关系的董事。 独立非执行董事应当独立履行职责，不受公司及其主要股东、实际控制人等 单位或者个人的影响。 独立非执行董事对公司及全体股东负有忠实与勤勉义 ...

康龙化成（北京）新药技术股份有限公司 董事会议事规则 中国 北京 2025 年 3 月 康龙化成（北京）新药技术股份有限公司 董事会议事规则 第一章 总 则 第一条 为规范公司行为，保证董事会依法行使职权，根据《中华人民共和 国公司法》（"《公司法》"）、公司股票上市地证券交易所上市规则(包括但不限于 《香港联合交易所有限公司证券上市规则》（"《上市规则》"）)、和《康龙 化成（北京）新药技术股份有限公司章程》（"《公司章程》"）的规定，制定本规 则。 第二条 公司设立董事会，董事会由股东大会选举产生，受股东大会委托， 负责经营管理公司的法人财产，是公司的经营决策机构，对股东大会负责。 第二章 董事会会议的提案、召集及通知程序 第五条 董事会会议分为定期会议和临时会议。 代表 1/10 以上表决权的股东、1/3 以上董事或者监事会、过半数独立非执 行董事可以提议召开董事会临时会议。董事长应当自接到提议后 10 日内，召集 和主持董事会会议。董事长认为必要时，可以决定召集和主持董事会临时会议。 证券监管机构要求公司召开董事会临时会议的，董事长应当自接到证券监管机构 的要求后十日内，召集和主持董事会会议。 第六条 ...

Financial Performance - For the year ended December 31, 2024, total revenue reached RMB 12,275.8 million, an increase of approximately RMB 737.8 million or 6.4% compared to the previous year[3] - The profit attributable to equity holders of the parent company was approximately RMB 1,793.4 million, representing a growth of 12.0% from RMB 1,601.1 million in 2023[3] - The net cash flow from operating activities was approximately RMB 2,576.7 million, a decrease of about 6.4% compared to RMB 2,753.5 million in the prior year[3] - The gross profit for the year was RMB 4,149.3 million, reflecting a slight increase of 1.3% from RMB 4,094.8 million in 2023[5] - The group reported a pre-tax profit of RMB 2,091,263 thousand for the year ended December 31, 2024, compared to RMB 1,837,887 thousand in 2023, reflecting an increase of approximately 13.8%[17] - Total revenue for the year ended December 31, 2024, was RMB 12,275,775 thousand, an increase from RMB 11,537,996 thousand in 2023, representing a growth of approximately 6.4%[21] Dividends and Earnings - The board proposed a final dividend of RMB 2.0 per share, amounting to a total of approximately RMB 354.2 million[3] - The proposed final dividend for the year ending December 31, 2024, is RMB 2.0 per 10 shares, totaling approximately RMB 354,186,000 (tax included)[34] - The basic earnings per share for the year ending December 31, 2024, is RMB 1.014, compared to RMB 0.903 for 2023, reflecting an increase of approximately 12.3%[37] Assets and Liabilities - Total non-current assets increased to RMB 16,319.2 million from RMB 15,602.3 million in 2023[8] - Current assets decreased to RMB 7,608.2 million from RMB 10,874.4 million in the previous year[8] - Total liabilities decreased from RMB 9,584.2 million in 2023 to RMB 5,480.5 million in 2024[9] - The total equity attributable to equity holders of the parent company increased to RMB 13,619.3 million from RMB 12,556.8 million in the previous year[9] Revenue Breakdown - The revenue breakdown by region for 2024 shows North America at RMB 7,852,729 thousand, Europe at RMB 2,271,934 thousand, and mainland China at RMB 1,847,332 thousand[18] - The laboratory services segment generated revenue of RMB 7,046,875 thousand, while the CMC services segment contributed RMB 2,988,773 thousand, indicating strong performance across these divisions[17] - Total revenue from the European market increased significantly from RMB 1,844,397 thousand in 2023 to RMB 2,271,934 thousand in 2024, marking a growth of approximately 23.2%[18] - Laboratory services revenue grew to RMB 7,046,875 thousand in 2024, up 5.8% from RMB 6,660,117 thousand in 2023[21] Research and Development - Research and development costs amounted to RMB 469.3 million, up from RMB 448.3 million in the previous year[5] - The company operates 21 R&D centers and production bases across China, the UK, and the US, enhancing its global drug development services[44] - The company has established a bioanalytical platform in China and the US to support global clinical trials for small molecules and biologics[50] - The company is currently managing 1,062 ongoing clinical trial projects, including 94 Phase III trials and 407 Phase I/II trials[67] Operational Efficiency and Technology - The company emphasizes enhancing operational efficiency and service capabilities to meet market demands[44] - The company has begun applying artificial intelligence tools in laboratory chemistry and plans to continue expanding investments in AI and automation to enhance research efficiency[61] - The company is actively exploring the application of AI and machine learning in process chemistry research and production optimization to improve CDMO service efficiency[64] - The company achieved significant progress in digitalization and intelligence within its clinical sector, integrating multiple AI applications across various business areas[68] Market Outlook and Strategy - The company aims to become a global leader in multi-therapy drug development services, focusing on small molecules, large molecules, and cell and gene therapies[44] - The company plans to enhance its large molecule drug discovery and CDMO service capabilities in 2025, establishing a quality system that adheres to the highest international regulatory standards[144] - The company aims to strengthen its cell and gene therapy service platform by leveraging synergies between its U.S. and U.K. operations, gradually expanding its customer base and operational efficiency[145] - The company recognizes the risk of declining demand in the drug development service market due to fluctuations in investment and budget changes from multinational pharmaceutical companies[149] Employee and Talent Management - The company has a total of 21,370 employees as of December 31, 2024, compared to 20,295 employees as of December 31, 2023, indicating a growth of approximately 5.3% in workforce[159] - The company is committed to attracting and retaining top talent to maintain its competitive edge in providing high-quality services[149] - The company will optimize its human resources management system to enhance talent attraction, assessment, training, and motivation mechanisms[150] Compliance and Risk Management - The company has established an audit committee consisting of three independent non-executive directors, ensuring compliance with applicable accounting principles and standards[176] - The company is actively monitoring changes in pharmaceutical policies and is committed to meeting regulatory requirements to avoid operational disruptions[152] - The company faces risks from international policy changes and trade tensions, which could adversely affect its operations in overseas markets[153] Shareholder Actions - The company repurchased a total of 9,608,288 A-shares at a total cost of approximately RMB 200.1 million during the reporting period, with all shares canceled by December 25, 2024[160] - The company repurchased 7,263,300 H-shares at a total cost of approximately HKD 99.8 million from December 2024 to January 2025, which are held as treasury shares[162] - The company conducted a series of repurchases and redemptions of convertible bonds totaling approximately USD 573.1 million during the reporting period[166] Strategic Partnerships and Acquisitions - The company signed a strategic cooperation agreement with AstraZeneca Investment (China) for integrated services in drug discovery and development, increasing its investment in the AstraZeneca fund to RMB 191 million, representing 8.46% of the total subscription[120] - The company completed the acquisition of approximately 78.5% of Shanghai Jiying Intelligent Technology Co., Ltd. and a controlling transaction with Zhejiang Haixin Zhihui Technology Co., Ltd. in February 2025[68] - The company plans to acquire a 51.39% stake in Hai Xin Zhi Hui for approximately RMB 185.0 million, expected to complete by February 2025, enhancing its capabilities in digital tumor patient management[172]

证券代码：300759 证券简称：康龙化成 公告编号：2025-010 康龙化成（北京）新药技术股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 一、投资事项概述 为充分运用专业投资机构在行业内投资、研判的能力，提高康龙化成（北京） 新药技术股份有限公司（以下简称"公司"）投资能力，同时促进宁波医药行业 的高质量发展，公司拟作为有限合伙人以自有资金认缴出资 10,000 万元人民币 参与投资宁波甬康股权投资合伙企业（有限合伙）（暂拟名称，以市场监督管理 机关核定的名称为准，以下简称"基金"或"合伙企业"）。2025 年 3 月 19 日， 公司签署了《关于宁波甬康股权投资合伙企业（有限合伙）（拟）之有限合伙协 议》（以下简称"合伙协议"）。 本次交易不构成关联交易，不构成《上市公司重大资产重组管理办法》规定 的重大资产重组情况。根据《深圳证券交易所创业板股票上市规则》《深圳证券 交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》等规则及 《公司章程》的规定，本次投资事项无需提交公司董事会及股东大会审议。 二、合作方基本情况 1、普通合 ...

证券代码：300759 证券简称：康龙化成 公告编号：2025-009 康龙化成（北京）新药技术股份有限公司 关于完成工商变更登记并换发营业执照的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 康龙化成（北京）新药技术股份有限公司（以下简称"公司"）于 2024 年 12 月 18 日召开的 2024 年第二次临时股东大会、2024 年第二次 A 股类别股东大 会及 2024 年第二次 H 股类别股东大会审议通过了《关于注销已回购股份并减少 注册资本的议案》，本次回购股份注销事宜已于 2024 年 12 月 25 日办理完成。 具体内容详见公司于 2024 年 12 月 26 日披露在巨潮资讯网（www.cninfo.com.cn） 的《关于回购股份注销完成暨股份变动的公告》（公告编号：2024-078）。 近日，公司办理完成相关内容的工商变更登记手续，并取得了北京经济技术 开发区市场监督管理局换发的《营业执照》。公司新换发的《营业执照》基本信 息如下： 统一社会信用代码：9111030276350109XG 名称：康龙化成（北京）新药技术股份有限公司 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 Pharmaron Beijing Co., Ltd. 康 龍 化 成（ 北 京 ）新 藥 技 術 股 份 有 限 公 司 董事會會議通告 康龍化成（北京）新藥技術股份有限公司（「本公司」）董事會（「董事會」）謹此宣 佈，董事會會議將於2025年3月26日（星期三）舉行，藉以（其中包括）審議及批准 本公司及其附屬公司截至2024年12月31日止年度業績，並考慮建議派發末期股息 （如有）。 承董事會命 康龍化成（北京）新藥技術股份有限公司 主席 樓柏良博士 中華人民共和國，北京 2025年3月12日 於本公告日期，董事會包括執行董事樓柏良博士、樓小強先生及鄭北女士；非執 行董事胡柏風先生及李家慶先生；獨立非執行董事李麗華女士、曾坤鴻先生及余 堅先生。 （於中華人民共和國註冊成立的股份有限公司） （股份代號：3759） ...

二、进展事项 近日，公司已获得北京市发展和改革委员会、北京市商务局等主管单位对本 次追加投资的备案。根据《Share Subscription Agreement (Capital Increase)》的约 定，本次追加投资的全部交割先决条件已满足，全体投资人已向合资公司足额支 付追加投资款，2025 年 3 月 10 日，合资公司完成股东名册更新登记。 | 股东名称 | 投资金额（美元） | 股份数量（股） | 股权比例 | | --- | --- | --- | --- | | Pharmaron (Hong Kong) International | 28,000,000 | 28,000,000 | 35% | | Limited | | | | | CMS MEDICAL | 27,040,000 | 27,040,000 | 33.8% | | VENTURE PTE. LTD. | | | | | Rxilient Health Pte. | 8,960,000 | 8,960,000 | 11.2% | | Ltd. | | | | 证券代码：300759 证券简称：康龙化成 公告编号：202 ...